If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Humulin® Therapies
Humulin® R (U-100) (regular insulin human injection, USP [rDNA origin])
100 units/mLHumulin® R (U-500) (regular U-500 [concentrated] insulin human injection, USP [rDNA origin])
500 units/mLHumulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin])
100 units/mLHumulin® N U-100 (human insulin [rDNA origin] isophane suspension)
100 units/mLThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What are Lilly's plans to ensure future insulin supplies?
Lilly will continue to do everything within our control to ensure those who rely on Lilly insulin can get the medicine they need.
Insulin Supply
Eli Lilly and company is aware of communications from Novo Nordisk on its decision to discontinue some presentations of insulin around the world. Recently, Lilly has been receiving questions from government entities and non-profit organizations around the world about our commitment to supplying insulin and if we can fill the gaps in future supply.
Lilly understands the importance of insulin and are committed to ensuring people have access to the medicines they need. As with all our products, we regularly monitor our supply chain and evaluate demand for our portfolio to help meet the needs of patients. If other manufacturers decrease supply or sunset certain insulin products, that will most likely increase global insulin supply demands on Lilly and could present constraints. We will continue to do everything within our control to ensure those who currently rely on Lilly insulin can get the medicine they need.
Date of Last Review: October 25, 2024